Evidence map›Paper›PMID 29240767›Full record

ArticlePLoS genetics2017

MITF - A controls branching morphogenesis and nephron endowment.

Aurélie Phelep, Denise Laouari, Kapil Bharti, Martine Burtin, Salvina Tammaccaro, Serge Garbay, Clément Nguyen, Florence Vasseur, Thomas Blanc, Sophie Berissi and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. MITF-the first 25 years.Genes & development · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 2 countries.

Aurélie PhelepINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Denise LaouariINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Kapil BhartiUnit on Ocular and Stem Cells Translational Research National Eye Institute, National Institutes of Health, Bethesda, MD, United States of America.
Martine BurtinINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Salvina TammaccaroINSERM U1016-CNRS UMR 8104, Université Paris Descartes, Institut Cochin, Paris, France.
Serge GarbayINSERM U1016-CNRS UMR 8104, Université Paris Descartes, Institut Cochin, Paris, France.
Clément NguyenINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Florence VasseurINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Thomas BlancINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Sophie BerissiINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Francina Langa-VivesCentre d'Ingénierie Génétique Murine, Institut Pasteur, Paris, France.
Evelyne FischerINSERM U1016-CNRS UMR 8104, Université Paris Descartes, Institut Cochin, Paris, France.
Anne DruilheINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Heinz ArnheiterScientist Emeritus, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Bethesda, MD, United States of America.
Gerard FriedlanderINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Marco PontoglioINSERM U1016-CNRS UMR 8104, Université Paris Descartes, Institut Cochin, Paris, France.
Fabiola TerziINSERM U1151-CNRS UMR 8253, Université Paris Descartes, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades, Paris, France.
Inserm · FRUniversité Paris Cité · FRCentre National de la Recherche Scientifique · FRHôpital Necker-Enfants Malades · FRInstitut Cochin · FRInstitut Necker Enfants Malades · FRInstitut Pasteur · FRNational Eye Institute · USNational Institute of Neurological Disorders and Stroke · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital nephron number varies widely in the human population and individuals with low nephron number are at risk of developing hypertension and chronic kidney disease. The development of the kidney occurs via an orchestrated morphogenetic process where metanephric mesenchyme and ureteric bud reciprocally interact to induce nephron formation. The genetic networks that modulate the extent of this process and set the final nephron number are mostly unknown. Here, we identified a specific isoform of MITF (MITF-A), a bHLH-Zip transcription factor, as a novel regulator of the final nephron number. We showed that overexpression of MITF-A leads to a substantial increase of nephron number and bigger kidneys, whereas Mitfa deficiency results in reduced nephron number. Furthermore, we demonstrated that MITF-A triggers ureteric bud branching, a phenotype that is associated with increased ureteric bud cell proliferation. Molecular studies associated with an in silico analyses revealed that amongst the putative MITF-A targets, Ret was significantly modulated by MITF-A. Consistent with the key role of this network in kidney morphogenesis, Ret heterozygosis prevented the increase of nephron number in mice overexpressing MITF-A. Collectively, these results uncover a novel transcriptional network that controls branching morphogenesis during kidney development and identifies one of the first modifier genes of nephron endowment.

Indexed as

AnimalsFemaleHumansKidneyMaleMiceMice, TransgenicMicrophthalmia-Associated Transcription FactorMorphogenesisNephronsOrganogenesisProtein IsoformsProto-Oncogene Proteins c-retUreterMicrophthalmia-Associated Transcription FactorProtein IsoformsProto-Oncogene Proteins c-retRET protein, humanRet protein, mouse

Identifiers

PMID29240767
PMCPMC5746285
OpenAlexW2775192515

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.